
The New York University Grossman School of Medicine Hub is conducting GLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): A Multi-Stage Observational and Pragmatic Trial in Criminal-Legal Settings. GLOW-UPS is a large multisite effectiveness-implementation trial to examine glucagon-like peptide-1 receptor agonist (GLP-1) usefulness among individuals with substance use disorders (SUD) involved in the criminal-legal system. Participating Departments of Corrections (DOCs) are located in Connecticut, Delaware, and New Hampshire. The study will be informed by Phase I formative research findings on feasibility and acceptability in carceral settings.
Stage 1: Survey and Interview Objectives
Stage 2: Clinical Trial Objectives:
Study Sites
Study Settings
Principal Investigators
Joshua D. Lee
MD, MS, New York University School of Medicine
Lisa Marsch, PhD
MD, Dartmouth College
Jan Gryczynski, PhD
Friends Research Institute
Sandra Springer
MD, MPH, Yale School of Medicine
Justice Agency Partner
-
Dr. Daniele Steele, DO, MPH, Medical and Forensic Services Director, New Hampshire DOC
- Alyssa Grant, Medical and Forensic Services Deputy Director, New Hampshire DOC
-
Morgan Suess, Director of the Addiction Treatment Unit, Connecticut DOC
- Mike Records, Chief of the Bureau of Healthcare, Substance Abuse and Mental Health Services, Delaware DOC